#IP13AVIDITY

Description Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...

📢 Join us at @IP_London

We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)

🔗 www.imperial.ac.uk/jobs/search-...

@londonprostate1.bsky.social @connorurol.bsky.social

‘Groundbreaking’ scan for men with prostate cancer could save lives Researchers hope the technology will help to create personalised treatment plans to prevent the disease becoming terminal

Thank you to @thetimes.com 📰for covering my first major grant success

- the £1.89M #IP13AVIDITY randomised trial testing PSMA PET defined and escalated treatment compared to standard of care for high-risk #prostatecancer @prostateukprofs.bsky.social

www.thetimes.com/uk/healthcar...

💬 "Whilst the new PSMA PET/CT scan does show up more areas, we do not yet know whether changing treatment based on the new scan actually makes a difference to survival. #IP13AVIDITY will give us that answer." @londonprostate1.bsky.social

‘Groundbreaking’ scan for men with prostate cancer could save lives Researchers hope the technology will help to create personalised treatment plans to prevent the disease becoming terminal

🚨 We're launching the £1.89M #IP13AVIDITY trial to test PSMA PET/CT scans for detecting & escalating #ProstateCancer treatment funded by @prostateuk.bsky.social

Co-led by @londonprostate1.bsky.social @connorurol.bsky.social #TaraBarwick #RhianGabe #AdamBrentnall

🗞️➡️ www.thetimes.com/uk/healthcar...